Market Update: Rapid Nutrition Launches SystemLS Subscription Model in the U.S.
Launch Aligns with U.S. Clinical Study and Accelerated Growth Strategy for 2025
London, United Kingdom – 4 March 2025 – Rapid Nutrition PLC (Euronext Growth: ALRPD), a global HealthTech company committed to advancing wellness through evidence-based solutions, has officially launched the SystemLS subscription model in the U.S., marking a significant milestone in the company’s global expansion strategy.
The strategic objective of this launch aligns closely with Rapid Nutrition’s participation in The Osteoarthritis Prevention Study (TOPS), a clinical trial conducted in collaboration with Wake Forest University. The study aims to evaluate the impact of a structured diet and exercise program—including two SystemLS Meal Replacements per day—compared to a Healthy Lifestyle Group that participates in group education sessions, over a 48-month period for weight management. The subscription model is designed to drive long-term customer engagement and create recurring revenue opportunities within the U.S. health and wellness market, which is valued at $1.2 trillion based on 2023 data.
"We are excited to expand into the U.S. with a subscription-based model, marking a transformative step for both our SystemLS brand and Rapid Nutrition," said Simon St Ledger, CEO of Rapid Nutrition. "We believe this strategic expansion represents the next wave of driving targeted revenue growth over the next 12 to 24 months."
This global initiative further strengthens Rapid Nutrition's ambassador program across Australia, Asia, and beyond, aiming to enhance brand awareness and promote product adoption.
About Rapid Nutrition
Rapid Nutrition is a global HealthTech company dedicated to advancing wellness through evidence-based, personalized nutrition solutions. Leveraging advanced technologies, AI, and scientific research, the company is committed to optimizing nutrition, improving health outcomes, and fostering sustainable, healthier lifestyles worldwide.
For more information, please visit http://rnplc.com
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).